DALLAS--(BUSINESS WIRE)--Heart Test Laboratories, Inc. (HTL), confirms that its Private Placement Stock Offering (“Offering”) will close on Friday, December 12, 2014 as scheduled in its Offering document. The Offering will remain open to investors until that time.
The Offering is available to accredited and institutional investors. A number of investors have already subscribed to and funded the Offering. Remaining subscriptions must be made prior to the last dates set out in the timetable below. The Company does not intend to extend the Offering beyond December 12, 2014. All funds are held in an independent bank administered escrow account in accordance with the terms set out in the Offering document.
The Company continues to make strong progress and is on track to commence sale of the MyoVista™ in September 2015 in accordance with its forecasts. The MyoVista™ is HTL’s proprietary medical device which enables the early detection of heart disease at low cost in a 10 minute non-invasive test.
Timetable for further subscriptions
5.00pm (US Central Time) Thursday, December 11th, 2014:
|Latest time for completed subscriptions documents to be received by HTL|
3.00pm (US Central Time) Friday, December 12th, 2014:
|Latest time for funds to be received into the bank escrow account|
Contact information to participate in the Offering
Copies of the Offering document and subscriptions documents are available on request from Paul Klotz at HTL (email@example.com) or telephone +1 682 237 7781.
About Heart Test Laboratories
HTL is a US based medical technology company founded in 2008 to develop and exploit the MyoVista™ which for the first time will enable effective wide scale screening for heart disease.
The MyoVista™ is a patented technology breakthrough medical device that offers significant advantages in the early identification of ischemic and other heart abnormalities. It is a portable, affordable device that is simple to use and very easy for a primary care physician to interpret. The MyoVista™ provides a 10 minute, at rest, noninvasive electrophysiology based device and is therefore significantly more cost-effective than other tests such as a CT scan, Nuclear Stress Test or Coronary Angiogram. It identifies myocardial abnormalities, ischemia and heart disease at an early stage.
HTL has benefited from 10 years and $10 million of R&D including clinical studies and field testing. The MyoVista™ is now fully developed and funding under the Offering is for sales and manufacture of the device and to expand the Company. Heart Disease is the biggest killer in the world. The MyoVista™ sits at the forefront of technology change. Its technology dramatically improves the sensitivity and accuracy of information about the heart using electrophysiology. Such technology will be highly sought after and become a global standard of care in non-invasive testing for heart disease at an early stage.